Cyproterone

Risk of meningioma

Europe. The EMA’s PRAC has started a review of cyproterone (e.g. Androcur®) which will investigate the risk of meningioma, a rare, usually non-malignant tumour of the membranes covering the brain and spinal cord.

Cyproterone is a steroidal antiandrogen, indicated for the treatment of a range of conditions, including excessive hair growth, prostate cancer, acne, and in hormone replacement therapy.

A recent study in France suggested a risk of meningioma with cyproterone use. The PRAC will examine available evidence and make recommendations.

Reference : EMA, 11 July 2019 (ema.europa.eu)